Myrtelle Reports Encouraging Clinical Data for MYR-101 Gene Therapy in Canavan Disease at ASGCT 2026
核心洞察
Myrtelle (搜索) announced encouraging clinical data from its first-in-class oligodendrocyte-targeting gene therapy MYR-101 for Canavan disease (搜索), demonstrating signals of therapeutic benefit and meaningful clinical improvement in treated children.
The company will present clinical trial results at the ASGCT Annual Meeting, highlighting progress in its FDA START Pilot Program participation and regulatory pathway toward BLA submission.
MYR-101 represents a novel AAV-mediated gene therapy approach targeting oligodendrocytes (搜索) to address the underlying ASPA (搜索) gene mutations that cause this fatal childhood neurodegenerative disease.
Myrtelle (搜索), Inc., a clinical-stage gene therapy company selected by the FDA for the START Pilot Program, announced encouraging clinical data from its first-in-class oligodendrocyte-targeting gene therapy program for Canavan disease (搜索). The company will present these results at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, demonstrating signals of therapeutic benefit and meaningful clinical improvement in children treated to date.
Clinical Data Presentation at ASGCT
Dr. Paola Leone, an internationally recognized leader in Canavan disease (搜索) research and scientific adviser to Myrtelle (搜索), will present clinical data from the company's ongoing study during the session "Beyond neurons: Glial-targeted gene and cell therapies for neurologic and ophthalmic diseases" on Tuesday, May 12th. Her presentation, titled "AAV Mediated Gene Therapy for Canavan Disease (Clinical Trial)," will focus on clinical data from Myrtelle's ongoing study.
"We're honored to present encouraging data from children treated to date at ASGCT, demonstrating signals of therapeutic benefit and meaningful clinical improvement, while contributing to the advancement of innovative gene therapy for Canavan disease (搜索)," said Dr. Leone.
Regulatory Progress and Manufacturing Partnership
Adrian Stecyk, Chief Executive Officer of Myrtelle (搜索), will serve as a guest presenter at a sponsored symposium hosted by Viralgen (搜索), the company's commercial manufacturing partner for MYR-101. The presentation will highlight the collaboration between Myrtelle and Viralgen, the status of Myrtelle's participation in the START Pilot Program, and the company's regulatory path toward BLA submission, including key data highlights from the gene therapy study.
"We are pleased to continue advancing MYR-101 in collaboration with Viralgen (搜索) and to share our progress with the ASGCT community," said Stecyk.
Understanding Canavan Disease
Canavan disease (搜索) is a fatal childhood genetic brain disease caused by mutations in the ASPA (搜索) gene, which prevent the normal expression of aspartoacylase (搜索), a critical enzyme produced in oligodendrocytes (搜索). The lack of normal aspartoacylase expression negatively impacts brain bioenergetics and development, including myelin production.
Patients with Canavan disease (搜索) are impacted at birth but may appear normal until several months old when symptoms begin to develop. Poor head control, abnormally large head size, difficulty in eye tracking, excessive irritability, severely diminished muscle tone, and delays in reaching motor milestones are typical initial manifestations. As the disease progresses, seizures, spasticity, difficulties in swallowing, and overall muscle deterioration emerge, with most affected children developing life-threatening complications by approximately 10 years of age.
Currently, there are no cures for Canavan disease (搜索), and only palliative treatments are available. Myrtelle (搜索)'s clinical trial information can be found on ClinicalTrials.gov under identifier NCT04833907.
Company Background
Myrtelle (搜索) Inc. focuses on developing transformative treatments for neurodegenerative diseases through its proprietary platform, intellectual property, and portfolio of programs supporting innovative gene therapy approaches. The company has an exclusive worldwide licensing agreement with Pfizer Inc. for its Canavan disease (搜索) program, positioning MYR-101 as a potentially transformative treatment for this devastating pediatric condition.